Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

BACKGROUND: To compare the efficacy of sorafenib and sunitinib with regard to overall survival (OS) and progression free survival (PFS) in Chinese patients with metastatic renal cell carcinoma (mRCC). METHODS: A multicenter, retrospective study was performed to elucidate the relationship between cli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Zhang, Hai-Liang, Sheng, Xi-Nan, Li, Xue-Song, Wang, Hong-Kai, Chi, Zhi-Hong, He, Zhi-Song, Ye, Ding-Wei, Guo, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5217658/
https://ncbi.nlm.nih.gov/pubmed/28056874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-3016-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados